
EC approves BMS’ Opdivo and Yervoy combo for HCC
The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the recombinant human monoclonal antibody Yervoy (ipilimumab) as a first-line treatment for adults with unresectable or advanced …